Allergan Announces Commercialization Collaboration With 3M Pharmaceuticals.

IRVINE, Calif.--(BW HealthWire)--Nov. 17, 1999--

Allergan, Inc. (NYSE: AGN) announced today that it has entered into a multi-year agreement with 3M Pharmaceuticals, a division of Minnesota Mining and Manufacturing Company (NYSE: MMM), to co-promote Allergan's proprietary acne product, Tazorac(R) (Tazarotene Gel 0.10%), in the U.S. dermatology market. Tazorac(R) was launched by Allergan in 1997 for mild to moderate plaque psoriasis and, recently, for facial acne vulgaris of mild to moderate severity. 3M Pharmaceutical's sales force began detailing and promoting Tazorac(R) to its dermatology practitioner base in early November.

"Allergan is extremely enthused about this co-promotion collaboration with 3M Pharmaceuticals, which has one of the most skillful dermatology sales forces in the United States," said David E.I. Pyott, President and Chief Executive Officer of Allergan. "The relationship with 3M Pharmaceuticals provides Allergan with an established, highly respected marketing partner committed to the commercial success of Tazorac(R) in the acne market. 3M's experience, and its related success in dermatology, made it an ideal co-promotion partner to co-launch Tazorac(R) for acne," continued Mr. Pyott. "As a co-promotion team, 3M and Allergan's combined efforts will dramatically increase Tazorac(R)'s call frequency upon dermatologists. Furthermore, this transaction is highly illustrative of Allergan's commitment to grow its dermatology franchise in the Americas via investing in the growth of Allergan developed products for acne and psoriasis."

Forward-looking Statements

Any of the above statements that refer to Allergan's estimated or anticipated future results or product performance are forward-looking and reflect the Company's current analysis of existing trends and information. Actual results may differ from current expectations based on a number of factors, including the level of success of the collaboration with 3M Pharmaceuticals and acceptance by physicians and patients of Tazorac(R) as a treatment for facial acne of mild to moderate severity. These forward-looking statements represent the Company's judgment only as of the date of this press release. Actual results could differ materially from expectations reflected in this release. Therefore, the reader is cautioned not to rely on these forward-looking statements. The Company disclaims any intent or obligation to update these forward-looking statements.

Additional information concerning these factors can be found in press releases as well as in Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Certain Factors and Trends Affecting Business" in Allergan's 1998 Form 10-K. These filings are available publicly and upon request from Allergan's Investor Relations Department: 714-246-4636 or on the internet at http://www.allergan.com.

Allergan, Inc. headquartered in Irvine, California, is a technology-driven, global health care company providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets that deliver value to our customers, satisfy unmet medical needs and improve patients' lives.

3M is a $14.2 billion, diversified, international corporation headquartered in St. Paul, Minn. 3M's health care businesses include pharmaceuticals, as well as medical, surgical, dental and consumer health care products. 3M Pharmaceuticals focuses on development of innovative products marketed as drug delivery systems and branded pharmaceuticals.